A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Pharmacokinetics of DUR-928 in Healthy Volunteers Following Daily Oral Dosing

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Pharmacokinetics of DUR-928 in Healthy Volunteers Following Daily Oral Dosing

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Fatty liver
  • Focus Pharmacokinetics
  • Sponsors INC Research
  • Most Recent Events

    • 16 Jul 2015 Status changed from recruiting to completed as per Australian New Zealand Clinical Trials Registry record.
    • 18 Jun 2015 Planned number of patients changed from 20 to 28 as per Australian New Zealand Clinical Trials Registry.
    • 18 Jun 2015 Status changed from active, no longer recruiting to recruiting as per Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top